

Template Version	FDP National DPIA Template (Pseudo) version 1.1 240424		
Document filename	Long COVID Dashboard – FDP National DPIA (Pseudo)		
Directorate / Programme	FDP Programme	Product Name	Long COVID Dashboard
Document Reference No	FDP 022NT	Information Asset Register Number	
Information Asset / Product Owner Name	Mat Gaule	Version	1.0
Author(s)	Lia Holmes (Senior Consultant Strategic IG NECS)	Version issue date	04/06/2024

Redaction Rationale – The information above for 'Information Asset/Product Owner' and 'Author(s)' has been redacted as this includes personal information, this has been completed in line with Section 40 (2) of the Freedom of Information Act 2000.

FDP Product Data Protection Impact Assessment – Long COVID Dashboard

Document Management

Revision History

Redaction Rationale – The information below has been redacted as this includes personal information, this has been completed in line with Section 40 (2) of the Freedom of Information Act 2000.

Version	Date	Summary of Changes
0.1	16/05/2024	Information input into the DPIA template and finalised
0.2	22/05/2024	DGG comments
0.3	28/05/2024	Reply to DGG comments and update
0.4	28/05/2024	Clean version updated
0.5	30/05/2024	[REDACTED] comments and updates
0.6	30/05/2024	Comments and updates addressed
0.7	30/05/2024	Clean version
0.8	03/06/2024	[REDACTED] comments and updates
0.9	04/06/2024	Response to [REDACTED] comments
1.0	04/06/2024	Finalisation of document

Reviewers

Redaction Rationale – The information below has been redacted as this includes personal information, this has been completed in line with Section 40 (2) of the Freedom of Information Act 2000.

This document must be reviewed by the following people:

Reviewer name	Title / Responsibility	Date	Version
Jon Moore	Deputy Director, Data Protection Officer	30/05/2024	V0.5
Jon Moore	Deputy Director, Data Protection Officer	03/06/2024	V0.8

Approved by

Redaction Rationale – The information below has been redacted as this includes personal information, this has been completed in line with Section 40 (2) of the Freedom of Information Act 2000.

This document must be approved by the following people:

Name	Title / Responsibility	Date	Version
[REDACTED]	Deputy Direction, Data Protection Officer		V1.0

Document Control:

The controlled copy of this document is maintained in the NHS England corporate network. Any copies of this document held outside of that area, in whatever format (e.g. paper, email attachment), are considered to have passed out of control and should be checked for currency and validity.

Contents

Purpose of this document	4
1. Consultation with Stakeholders about the Product	8
2. Data Flow Diagram	10
3. Description of the Processing	10
4. Purpose of Processing Personal Data for this Product	11
5. Identification of risks	12
6. Compliance with the Data Protection Principles - for Processing Personal Data only	14
7. Describe the legal basis for the Processing (collection, analysis or disclosure) of Data?	14
8. Demonstrate the fairness of the Processing	15
9. What steps have you taken to ensure individuals are informed about the ways in which their Personal Data is being used?	16
10. Is it necessary to collect and process all Data items?	16
11. Provide details of Processors who are Processing Personal Data in relation to this Product	18
12. Describe if Data is to be shared from the Product with other organisations and the arrangements in place for this	18
13. How long will the Data be retained?	19
14. How you will ensure Personal Data is accurate and if necessary, kept up to date	19
15. How are individuals made aware of their rights and what processes do you have in place to manage requests to exercise their rights?	20
16. What technical and organisational controls in relation to information security have been put in place for this Product?	20
17. In which country/territory will Data be stored or processed?	21
18. Do Opt Outs apply to the Processing?	21
19. Risk mitigations and residual risks	22
20. Actions	30
21. Completion and signatories	30
22. Summary of high residual risks	30
Annex 1: Defined terms and meaning	32

Purpose of this document

A Data Protection Impact Assessment (DPIA) is a useful tool to help NHS England demonstrate how we comply with data protection law.

DPIAs are also a legal requirement where the Processing of Personal Data is “*likely to result in a high risk to the rights and freedoms of individuals*”. If you are unsure whether a DPIA is necessary, you should complete a DPIA screening questionnaire to assess whether the Processing you are carrying out is regarded as high risk.

Generally, a DPIA will not be required when Processing Operational Data which is not about individuals. However, a DPIA may be required when Processing Aggregated Data which has been produced from Personal Data, in order to provide assurance that the Aggregated Data is no longer Personal Data

By completing a DPIA you can systematically analyse your Processing to demonstrate how you will comply with data protection law and in doing so identify and minimise data protection risks.

Defined Terms used in this DPIA

Defined terms are used in this DPIA where they are capitalised. When drafting the DPIA, those defined terms should be used for consistency and clarity. The defined terms and their meanings are set out in [Annex 1](#). Not all terms in Annex 1 may be used in the DPIA.

Standard wording in this DPIA

Standard wording has been suggested in certain parts of this DPIA and highlighted yellow with square brackets around the text. You should select the wording that reflects the Processing of Data for the specific Product you are assessing and remove the square brackets, highlighting and wording you do not need to use eg:

- [For Data ingested into the FDP to create the Product]
- [For Data ingested into the Product to create the Product]

You would amend this where Data is ingested into the Product as follows:

- {For Data ingested into the FDP to create the Product}
- ~~• [For Data ingested into the Product to create the Product]~~

The aims of the Federated Data Platform (FDP)

Every day, NHS staff and clinicians are delivering care in new and innovative ways, achieving better outcomes for patients, and driving efficiency. Scaling and sharing these innovations across the health and care system in England is a key challenge for the NHS.

Harnessing the power of digital, Data and technology is the key to recovering from the pandemic, addressing longer-term challenges, and delivering services in new and more sustainable ways.

The future of our NHS depends on improving how we use Data to:

- care for our patients;
- improve population health;
- plan and improve services; and
- find new ways to deliver services.

The Federated Data Platform (FDP)

A 'Data platform' refers to software which will enable NHS organisations to bring together Data – currently stored in separate systems – to support staff to access the information they need in one safe and secure environment so that they are better able to coordinate, plan and deliver high quality care.

A 'federated' Data platform means that every hospital trust and integrated care board (ICB) (on behalf of the integrated care system (ICS)) will have their own platform which can connect and collaborate with other Data platforms as a "federation" making it easier for health and care organisations to work together.

A digitised, connected NHS can deliver services more effectively and efficiently, with people at the centre, leading to:

1. Better outcomes and experience for people

A more efficient NHS ultimately means a better service for patients, reduced waiting times and more timely treatment. The platform will provide ICBs with the insights they need to understand the current and future needs of their populations so they can tailor early preventative interventions and target health and care support. Patients will have more flexibility and choice about how and where they access services and receive care, helping them to stay healthy for longer.

2. Better experience for staff

NHS staff will be able to access the information they need in one secure place. This reduces the time they spend chasing referrals, scheduling appointments, and waiting for test results and allows them to work more flexibly to deliver high quality care for their patients.

3. Connecting the NHS

The connectivity of the platforms is extremely important as it will enable us to rapidly scale and share tools and applications that have been developed at a local level – in a secure way – supporting levelling up and reducing variation across England.

Federation means that each Trust and ICB has a separate Instance of the platform for which they are the Controller. Access for each Instance will be governed and managed by each individual organisation.


We want the NHS to be the best insight-driven health and care system in the world. This software will provide the foundation to improve the way that Data is managed and used across the NHS in England to transform services and save lives.

The FDP will not only provide the cutting-edge software to Trusts and ICBs to continue to innovate but the connectivity will enable NHS England (NHSE) to rapidly scale and share innovative solutions that directly addresses the challenges most pressing for the NHS. This will transform the way the NHS delivers its services enabling organisations to communicate and collaborate more effectively and provide better care for patients.

The 'Product' Data Protection Impact Assessment (DPIA)

As part of the roll out of FDP, NHS England wants to enable Trusts and ICBs to use standard FDP Products as this will reduce burden for those organisations in creating their own analytical tools and will provide a consistent approach to how Data is used in relation to the five use cases and capabilities as shown in the diagram below.

A Product DPIA is part of a suite of DPIAs for FDP that sit under the overarching FDP DPIA and provide a mechanism for assessing data protection compliance at a detailed Product level. NHS England teams have created template Product DPIAs to help NHS England, NHS Trusts and ICBs comply with UK GDPR and the FDP IG Framework.



Key information about the Product
Purpose of the Product - Overview
<p>This Product has been implemented to enable NHS England and ICBs to monitor the effectiveness of Long COVID services for patients.</p> <p>Long COVID, or Post-COVID-19 Syndrome, is a condition where individuals continue to experience symptoms of COVID-19 for a long period after a COVID-19 infection.</p> <p>NHS Long COVID services, can offer patients: further tests to help diagnose or monitor symptoms; assessments for patients’ physical and mental health; treatment for or help managing long COVID symptoms; and referral to Long COVID rehabilitation for further support, if needed.</p> <p>The Product produces a Dashboard (the Dashboard). The Dashboard provides information to NHS England, both regional and national teams, and ICBs, regarding wait times, referral dates and follow up appointments for Long COVID services as well as demographic Data on individuals accessing the services.</p> <p>To create the Dashboard in this Product, Pseudonymised Data is used but the Dashboard only displays Aggregated Datasets.</p> <p>The Product falls under the Care Co-Ordination Use Case as the Dashboard provides information to support patients receiving treatment through Long COVID care services and enables care to be co-ordinated across areas.</p> <p>This Product also falls under the Population Health Management Use Case as it allows NHS organisations to identify areas it needs to provide additional services targeted at supporting Long COVID patients, i.e. those areas with either a high level of Long COVID patients or which have limited Long COVID support services.</p>

Local or National Product		
Local	<input type="checkbox"/>	National <input checked="" type="checkbox"/>
Product falls under the following Use Case(s)		
Care co-ordination	<input checked="" type="checkbox"/>	To ensure that health and care organisations all have access to the information they need to support the patient, enabling care to be coordinated across NHS services.
Elective Recovery	<input type="checkbox"/>	To get patients treated as quickly as possible, reducing the backlog of people waiting for appointments or treatments, including maximising capacity, supporting patient readiness and using innovation to streamline care.
Vaccination and Immunisation:	<input type="checkbox"/>	To ensure that there is fair and equal access, and uptake of vaccinations across different communities.
Population Health Management	<input checked="" type="checkbox"/>	To help local trusts, Integrated Care Boards (on behalf of the integrated care systems) and NHS England proactively plan services that meet the needs of their population.
Supply Chain	<input type="checkbox"/>	To help the NHS put resources where they are needed most and buy smarter so that we get the best value for money.
Categorisation of the Data used to create the Product		How the different Categories of Data are used in relation to the Product
Directly Identifiable Personal Data	<input type="checkbox"/>	
Pseudonymised Data	<input checked="" type="checkbox"/>	For Data ingested into the FDP to create the Product. The Data ingested is listed in the Data Specification in Section 10.
Anonymised Data	<input type="checkbox"/>	
Aggregated Data	<input checked="" type="checkbox"/>	For Data displayed or shared with users of the Product
Operational Data	<input type="checkbox"/>	
Type of Data used in the Product		
No Personal Data	<input type="checkbox"/>	

Personal Data	<input checked="" type="checkbox"/>	For Data ingested into the FDP to create the Product For Data ingested into the Product to create the Product
Special Category Personal Data	<input checked="" type="checkbox"/>	For Data ingested into the FDP to create the Product For Data ingested into the Product to create the Product

The Product DPIAs describe:

- the purpose for the creation of the Product;
- the Data which has been processed to create the Product. Where Aggregated Data is ingested into FDP, a DPIA is still carried out to provide assurance that the Aggregated Data is not Personal Data;
- the supporting legal basis for the collection, analysis and sharing of that Data;
- the Data flows which support the creation of the Product, and;
- the risks associated with the Processing of the Data and how they have been mitigated.

National Product DPIAs

The Products described in the national Product DPIAs relate to NHS England's use of the Product and related Data in the national Instance of the platform, and therefore all risks and mitigations of those risks contained within the DPIA are only applicable to NHS England.

Local Product DPIAs

The Products described in the template local Product DPIAs relate to an NHS Trust or ICB use of the Product and related Data in a local Instance of the platform, and therefore all risks, and mitigations of those risks, contained within the DPIA are only applicable to Trusts and ICBs.

NHS Trusts and ICBs who use the Products made available to them are responsible for adopting and updating the template local Product DPIA or producing their own DPIA to reflect their specific use of the Product and to assess any specific risks relating to their organisation's use of the Product.

1. Consultation with Stakeholders about the Product

The Long COVID Dashboard is derived from the Long COVID Assessment Clinic Patient List Data collection (DAPB4027).

When NHS England established this collection, it carried out a range of engagement with stakeholders including:

- Providers of Long COVID services in England (114 organisations), including Acute Trusts, Community Trusts and Mental Health Trusts. These organisations have been consulted on the concept of the collection prior to commencement and engaged to agree the Data set content and specification. Feedback has been gathered from these organisations on an ongoing basis regarding the data specification and operation of the collection. This has informed further development and refinement of the collection.


- NHS England regional teams have been consulted on progress of the data set development and standards for providers.
- Arden & GEM Commissioning Support Unit (AGEM) has been consulted on feasibility and technical operation for the Data collection.
- Patient representative groups (NHS England Long COVID Patient and Public Voice partners) and clinician networks were consulted prior to establishment of the Data collection and provided feedback validating the need for the patient level Data collection and NHS Long COVID registry.
- The Department of Health and Social Care has provided feedback supporting the establishment of the patient level Data collection and NHS Long COVID registry.
- Health Data Research UK and National Institute for Health and Care Research funded research teams have been consulted on how insights may be harnessed from the Data, how Data from the collection may be used in research in Long COVID and engaged in partnerships for evaluation work.
- Public Health England, whose responsibilities now sit with UK Health Security Agency (UKHSA), has been engaged to coordinate analysis related to Long COVID.
- The Data Standards and Assurance Service (DSAS), Advisory Group for Data (AGD) and Caldicott Guardian have been consulted in relation to the collection.

In the establishment and development of the Long COVID Dashboard on the National Data Platform, NHS England has consulted with the following:

- Service leads for Long COVID services in England, who are users of the Dashboard. They have been consulted on the design, functionality and user experience of the Dashboard.
- Business intelligence professionals and leads for Long COVID services in England, who are data submitters to the collection and users of the Dashboard, have been consulted to assure and verify data quality and on the design, functionality and user experience of the Dashboard.
- Integrated Care Systems, NHS England regional and national strategic leads and managers with responsibility for commissioning, development and oversight of Long COVID services, who are users of the Dashboard, been consulted on the design, functionality and user experience of the Dashboard.
- AGEM technical personnel have been consulted on technical design of the Dashboard.
- Data Management Integration Services (DMIS) and Foundry engineers were consulted on technical design of the Dashboard, access controls, and access to linked datasets.

Feedback has been gathered on an ongoing basis through a number of channels, including webinars, Long COVID steering group, programme board and network meetings, and has informed further development and refinement of the Dashboard.

2. Data Flow Diagram



3. Description of the Processing

The Data for this Product is Pseudonymised by AGEM and ingested into FDP in Pseudonymised format.

This includes the Data items listed below:

- AGE_AT_CDS_ACTIVITY_DATE: Age of patient on activity date (e.g. visit to Long COVID service) derived from patient's date of birth and activity date.
- ICB_CODE: Integrated Care Board covering the area in which the patient's postcode falls.
- CONSTITUENCY_CODE: Constituency covering the area in which the patient's postcode falls.
- DIST_UNITARY_AUTH: District Unitary Authority covering the area in which patient's postcode falls.
- LOCAL_AUTH: Local Authority covering the area in which the patient's postcode falls
- LSOA_CODE: Lower Super Output Area covering the area in which the patient's postcode falls
- MSOA_CODE: Middle Layer Super Output Area Code covering the area in which the patient's postcode falls.

This Data is loaded into the COVID-19 Data Store in FDP where it is accessible to NHS analysts who have the necessary permissions.

Within FDP, the Data is processed through an analysis pipeline, which includes data quality check and data cleaning (e.g. removal of duplicate records) on a Code Workbook.

The Data is linked to relevant data sets using a patient pseudo-ID. This allows NHS England to add additional pseudonymised information to the Data such as:

- demographic information;
- NHS staff information; and
- NHS secondary care activity data.


The additional Pseudonymised Data will allow subsequent analysis on the impact of Long COVID and access to services of different populations.

Following data analysis, the Aggregate Data is displayed in a Dashboard on FDP. The Dashboard includes: demographic Data on patients accessing the Long COVID services; data about referrals; initial assessments; follow up appointments; and waiting times in the Long COVID services. This information is provided at national, regional, ICS and provider level.

4. Purpose of Processing Personal Data for this Product

The key objectives of the Product, Dashboards within it, are to:

- Support delivery of Long COVID services in England. The Dashboard provides robust and nationally consistent information on activity and performance of NHS-funded Long COVID services located in England, which provide specialist care for patients with Long COVID (ongoing symptomatic COVID-19 and Post-COVID-19 Syndrome)
- Enable NHS organisations to comply with the NHS Plan for 2021/22 and The NHS plan for improving Long COVID Services, which set out commitments to establish Long COVID services, providing access to specialist diagnosis, treatment and rehabilitation.
- Enables the NHS to demonstrate delivery of the Long COVID plan commitments and supports commissioning, service design and planning, delivery, monitoring, and assurance of Long COVID services.
- Provide a high data quality and accurate Dashboard to the NHS through using Pseudonymised Data to create an Aggregate Data Dashboard.



Redaction rationale:

The screenshots above have been redacted due to the small numbers held within them. this has been completed in line with Section 40 (2) of the Freedom of Information Act 2000.

5. Identification of risks

This section identifies inherent risks of your Data Processing and potential harm or damage that it might cause to individuals whether physical, emotional, moral, material or non-material e.g. inability to exercise rights; discrimination; loss of confidentiality; re-identification of pseudonymised Data, etc.

This section is used to detail the risks arising from the proposed Processing Data if there are no steps in place to mitigate the risks. The sections below will then set out the steps you will take to mitigate the risks followed by a second risk assessment which considers the residual risk once the mitigation steps are in place.

Risk No	Describe source of the risk and nature of potential impact on individuals <i>The highlighted text are the most identified risks in the programme. Please amend and delete as appropriate and add Product specific risks. If the Data being processed is Directly Identifiable Personal Data, the risks will be different from below and you should refer to this category of Data. If the Data being processed is only Aggregated Data, then most of the risks below, other than small number suppression, may not be relevant.</i>
1	There is a risk that Pseudonymised Data may be accidentally misused by those with access
2	There is a risk that Pseudonymised Data will be processed beyond the appropriate retention period
3	There is a risk that insufficient organisational measures are in place to ensure appropriate security of the Pseudonymised Data (e.g. policies, procedures, disciplinary controls)
4	There is a risk that insufficient technical measures are in place to ensure appropriate security of the Pseudonymised Data (e.g. encryption, access controls)
5	There is a risk that Pseudonymised Data could be deliberately manipulated by an internal bad actor in some way to re-identify individual people
6	There is a risk that unsuppressed small numbers in Aggregated Data made available via the Product Dashboard could lead to the identification of an individual
7	There is a risk that insufficient testing has taken place to assess and improve the effectiveness of technical and organisational measures.
8	There is a risk of failure to provide appropriate transparency information to data subjects.
9	There is a risk that increased access to Special Category Personal Data is given to NHS England staff who would not normally access that Data within their role.
10	There is a risk that the platform becomes inaccessible to users which could cause delays in the management of patient care and availability of Data.
11	There is a risk that inadequate data quality in source IT systems results in errors, inconsistencies and missing information that could compromise the integrity and reliability of the Data in the Product.
12	There is a risk that users will attempt to access FDP and the Product from outside the UK, increasing the data security risk.

13	There is a risk that users will not have their permissions revoked when they leave their role/organisation.
----	---

6. Compliance with the Data Protection Principles - for Processing Personal Data only

Compliance with the Data Protection Principles in relation to the Processing of Personal Data, as set out in Article 5 of the UK General Data Protection Regulation, are addressed in this DPIA in the following sections:

Data Protection Principle	Section addressed in this DPIA
Lawfulness, fairness and transparency	Section 7 (Lawfulness); Section 8 (Fairness); Section 9 (Transparency) and 11 (Processors)
Purpose limitation	Section 4
Data minimisation	Section 10
Accuracy	Section 14
Storage limitation	Section 13
Integrity and confidentiality (security)	Section 12 & 16
Accountability	Accountability is addressed throughout the DPIA. In particular, Section 21 includes approval of the residual risks by the Information Asset Owner and on behalf of the SIRO.

7. Describe the legal basis for the Processing (collection, analysis or disclosure) of Data?

<p>Statutory authority: This is for national Products only, please remove the Datasets which are not applicable and remove the highlight and/or amend as necessary.</p> <p>NHSE's various statutory authorities for collecting, Processing, analysing and sharing Data are set out in the table below.</p>			
Source Dataset	Statutory Authority for collection of Data	Statutory Authority for Processing & Analysis of Data	Statutory Authority for sharing of Data
COVID-19 Data	COVID-19 public health NHS England Directions 2020	NHS England De-Identified Data Analytics and Publication Directions 2023	Health and Social Care Act 2012 s.261(5)(d) and s.13Z3 (e) and (f)

Legal basis under UK GDPR & Data Protection Act 2018 (DPA 2018):

Article 6 – Personal Data

- Article 6(1)(c) Processing is necessary for compliance with a legal obligation, where NHS England collects and analyses Data under the Directions listed above (**Legal Obligation**).

Article 9 – Special Category Personal Data

- Article 9(2)(g) Processing is necessary for reasons of substantial public interest, where NHS England is Processing under Legal Obligation under Direction or Public Task, (**Substantial public interest**), plus Schedule 1, Part 2, Paragraph 6 '*statutory etc and government purposes*' of DPA 2018

Common Law Duty of Confidentiality

Legal obligation – NHSE is required by law to process Confidential Patient Data it collects, Pseudonymises and analyses to create the Pseudonymised Data input and Aggregated Data output for the Product. This is required under legal directions referred to above and issued by the Secretary of State for Health and Social Care to NHSE under section 254 of the Health and Social Care Act 2012.

8. Demonstrate the fairness of the Processing

Fairness means that we should handle Personal Data in ways that people would reasonably expect and not use it in ways that have an unjustified adverse impact on them.

The Product will have its own transparency information which sets out why the Processing is fair in what it is intended to achieve to improve the care of patients. Further information is set out in section 9 below.

Regarding the impact on individuals, the purpose of the Product provides a Dashboard highlighting the impact of Long COVID and access to services of different populations, which falls within Vaccination and Immunisation use case.

The impact for individuals of NHS England Processing this Data is to ensure that there is allocated funding to the appropriate Long COVID-19 services across England, allowing access to patients who require treatment from these services.

This Product allows NHS England National and Regional Leads and ICBs to review the services being provided and identify gaps where the services are required. NHS England is Processing Data in the Product to enable the NHS to operate effectively and to benefit patient care.

9. What steps have you taken to ensure individuals are informed about the ways in which their Personal Data is being used?

There is a range of information available on the NHS England website about FDP and how it works. This is Level 1 Transparency information.


There is a general FDP Privacy Notice which has been published via the NHS England webpages which also explains what FDP is and how it works in more detail. This is Level 2. It has a layered approach which has further detail in Level 3.

[NHS England » NHS Federated Data Platform privacy notice](#)

There is also a privacy notice specifically for this Product at Level 4 available via this link:

[NHS England » FDP products and product privacy notices](#)

FDP Programme – Privacy Notice and Transparency Information Suggested Approach based on User Research



V1.0 19/03/24

10. Is it necessary to collect and process all Data items?

All of the Personal Data items processed for this Product are Pseudonymised and or have been derived to create Aggregated Data before flowing into FDP. The items listed below are therefore only items which are Pseudonymised Data items flowing into FDP or the Product

Data Categories [Information relating to the individual's]	Yes/No	Justify [there must be justification for Processing the Data items. Consider which items you could remove, without compromising the purpose for Processing]
Personal Data		
Name	No	
Address	No	
Postcode	Yes	The Postcode is derived to support the creation of geographical derivations and understand Long COVID service activity within regions/ICSSs.
Date of Birth	Yes	DOB is derived to month and year of birth in the Pseudonymised Data which is used to create this Product. The Data is used to understand demographics of patients

Data Categories [Information relating to the individual's]	Yes/No	Justify [there must be justification for Processing the Data items. Consider which items you could remove, without compromising the purpose for Processing]
		accessing Long COVID services and for equality monitoring.
Age	Yes	To show demographic differences in metrics, this is derived from DOB as above.
Sex	No	
Marital Status	No	
Gender	Yes	To understand demographics of patients accessing Long COVID services and for quality monitoring.
Living Habits	No	
Professional Training / Awards / Education	No	
Email Address	No	
Physical Description	No	
General Identifier e.g. NHS No	Yes	A Pseudonymised Identifier is used and NHS Number
Home Phone Number	No	
Online Identifier e.g. IP Address/Event Logs	No	
Mobile Phone / Device No / IMEI No	No	
Location Data (Travel / GPS / GSM Data)	No	
Device MAC Address (Wireless Network Interface)	No	
General Medical Practice Code	Yes	The organisation code for the GP practice the patient is registered at, needed to enable verification of region and ICS classification of patient.
Special Category Data		
Physical / Mental Health or Condition, Diagnosis/Treatment	Yes	<ul style="list-style-type: none"> • Date the patient attended a Long COVID Service • Organisation code for the Long COVID Service the patient attended • The type of contact they had (whether a referral, clinical triage, initial assessment, follow up assessment, or referral closure) • Date the patient was referred to the Long COVID Service • The source of referral to the Long COVID Service • The reason for referral closure if applicable • The reason for referral rejection if applicable <p>Can infer from this that the patient has symptoms of and/or a diagnosis of Long COVID.</p> <p>Required to support the monitoring and evaluation of the Long COVID services, including access and waiting times and performance metrics specified by national commissioning guidance; and importantly, understanding and reducing variation in care, and monitoring health inequalities to enable these to be addressed.</p>
Sexual Life / Orientation	No	
Religion or Other Beliefs	No	
Racial / Ethnic Origin	No	
Biometric Data (Fingerprints / Facial Recognition)	No	
Genetic Data	No	
Criminal Conviction Data		
Criminal convictions / alleged offences / outcomes / proceedings / sentences	No	

Please see the detailed Data Specification below which identifies the source Datasets and specific Data items:

- [Post COVID Assessment Clinic Data Specification](#)

11. Provide details of Processors who are Processing Personal Data in relation to this Product

- The Platform Contractor is a Processor acting on behalf of NHS England as a Controller in relation to Processing Pseudonymised Data held on the Platform, and which is used in the Product. The Platform Contract has required Data Processing provisions in it which meet the requirements of UK GDPR. In addition, a separate Data Processing Annex providing specific Processing instructions to the Platform Contractor for this Product will be issued.

12. Describe if Data is to be shared from the Product with other organisations and the arrangements in place for this

Users of the Dashboard may include:

- ICBs who have access to Aggregated Data and who use the Dashboard for support to the organisation on viewing the effect of Long COVID in their area and the requirement of services.
- National and Regional NHS England Teams who have access to Aggregated Data and who use the Dashboard for information on the effect of Long COVID across the country and the services implemented currently, this supports the allocation of funding that has been provided to ICBs to commission Long COVID services in their area.
- Data Analysts and from organisations providing the initial datasets who have access to Aggregated Data and who use the Dashboard to view the effects of Long COVID on the nation and the services implemented.

Access is granted by Product Owner (Nasir Mahmood) in NHS England Data & Analytics. Access to the Long COVID Dashboard is available for:

1. Staff members in NHS organisations who have role in delivery, management and/or commissioning of NHS Post COVID services.
 1. Examples of this include clinicians, managers, business intelligence or data analysts in NHS provider organisations, Integrated Care Systems, NHS England regional organisations, and national NHS England.
2. Staff members in NHS England national teams who have role in data collection, data engineering and/or data analysis related to Long COVID data.

When requesting access, individuals in category (1) may only request USER access and must provide their job title and details of their role in the delivery, management and/or commissioning of NHS Post COVID services.

When requesting access, individuals in category (2) may request either USER or DEVELOPER access and must provide their job title and details of their role in data collection, data engineering and/or data analysis related to Long COVID data.

Access if reviewed according to fulfilment of above criteria, by Product Owner (Nasir Mahmood)

Access is revoked if user notifies that no longer meets above criteria or is known not to meet above criteria, by Product Owner (Nasir Mahmood)

13. How long will the Data be retained?

The Data will be kept in line with business requirements for the purposes of providing the Product. At the point that the Product is decommissioned, a further assessment will be undertaken to ascertain whether the Data can be destroyed, or a retention period agreed in line with the [NHS Records Management Code of Practice 2021](#).

14. How you will ensure Personal Data is accurate and if necessary, kept up to date

A number of measures are in place at each stage in the data design, collection and processing cycle to ensure data collected about individuals is accurate and kept up to date:

- Data items collected in the data set conform to the NHS Data Model and Dictionary Service standards. Any changes to the dataset must first be assessed and approved by the Data Alliance Partnership Board (DAPB) to ensure that the proposed changes are relevant and don't add undue burden on care providers.
- At the point of submission, validation checks are performed, and data is only be accepted if it passes the validation criteria (including maximum field length, rejection of null Organisation Identifier and non-conforming date formats)
- Detailed guidance materials are made available in relation to expected data submission. NHS England has worked closely with data submitters to continuously review and improve data quality, including targeted support to providers with errors.

Data submitters can report inaccuracies and/or errors to the national team, and make corrected submissions. The data processing and analysis pipeline underlying the Product automatically deduplicates patient records and selects for the most recently submitted, deleting prior erroneous records.

15. How are individuals made aware of their rights and what processes do you have in place to manage requests to exercise their rights?

General privacy information regarding the FDP is available in the FDP Privacy Notice on the NHSE website together with a Product specific Privacy Notice which sets out the rights which apply in relation to this Product.

The following rights under UK GDPR apply to the Processing of Pseudonymised Data to produce this Product:

- Right to be informed
- Right of access
- Right to rectify

Any requests would be handled by the DPO & Trust Team in NHS England in accordance with standard processes.

16. What technical and organisational controls in relation to information security have been put in place for this Product?

Redaction Rationale – The information below has been redacted as this includes information relating to information security within NHS England, this has been completed in line with Section 31 (1)(a) of the Freedom of Information Act 2000.

The Overarching FDP DPIA (and where applicable, NHS-PET DPIA) sets out the technical and organisational controls for the Platform and the NHS-PET Solution.

Business Continuity Arrangements

Should the FDP processing fail, the ability to undertake the processing using UDAL as a backup platform would be implemented.

Specific Access controls for this Product

Access permissions to the Dashboard will be granted via NHS Mail accounts. This is the standard methodology on NHS England's cloud infrastructure for the applications which are accessing the Data through the Database connections or API (Application Programming Interface). The Azure Bastion will control the access to the analytical tooling Virtual Machines.

Following this, an SQL account will be created which the application will use to read/write the Database for certain task(s). This will restrict unwarranted access.

A small number of NHSE and CSU Analysts, responsible for delivery of the Dashboard, will have secure permission-based access to the Pseudonymised Data within FDP in order to manage the required Dashboard aggregate-level visualisations for the users.

The Product Owner and IAO will be required to approve user access based on the Purpose Based Access Controls in place for the Product this is dependent on approved User or Developer access to the Product. Access to the Product is managed by the purpose lead, and approval is granted based on an individual being in a relevant role and organisation and satisfying at least one of following criteria:

1. Staff member in NHS organisations with direct role in delivery, management and/or commissioning of NHS Long COVID services. This may include clinicians, managers, business intelligence or data analysts in NHS provider organisations, Integrated Care Systems, NHS England regional organisations, and national NHS England.
2. Staff member in NHS England national team who have role in data collection, data engineering and/or data analysis related to Long COVID data.

When requesting access, individuals must provide sufficient information to meet the above criteria. Individuals in category (1) may only request USER access. Individuals in category (2) may request either USER or DEVELOPER access as relevant for their role.

17. In which country/territory will Data be stored or processed?

All Processing of Data will be within the UK only, this is a contractual requirement and one of the key principles of the FDP IG Framework

18. Do Opt Outs apply to the Processing?

The National Data Opt Out policy does not apply to this Product as the collection and analysis of Data by NHS England to create the Product has been carried out under a legal obligation (the Legal Direction) and therefore the National Data Opt out does not apply.

Type 1 Opt Outs do not apply to this Product because the Datasets used to create the Product does not contain Confidential Patient Information that has been collected by NHS England from GP Practices.

19. Risk mitigations and residual risks

Section 4 of this DPIA sets out the inherent risks arising from the proposed Data Processing. This section summarises the steps to mitigate those risks (which are explained in detail above) and assesses the residual risks, i.e. the level of risk which remains once the mitigations are in place.

Against each risk you have identified at section 4, record the options/controls you have put in place to mitigate the risk and what impact this has had on the risk. Make an assessment as to the residual risk.

Also indicate who has approved the measure and confirm that responsibility and timescales for completion have been integrated back into the project plan.

Risk No	Risk	Steps to mitigate the risk	DPIA section in which step is described	Effect on risk. Tolerate / Terminate / Treat / Transfer	Likelihood of harm Remote / Possible / Probable	Severity of harm Minimal / Significant / Severe	Residual risk None / Low / Medium / High
1	Pseudonymised Data may be accidentally misused by those with access	1. External suppliers are Processors on contracts with relevant security and data protection clauses contained within the agreements. Internal security and data protection processes are in place within NHS England. 2. No external users have access to Pseudonymised Data through the Dashboards in the Product. All internal users are required to sign security operating procedures that confirm their responsibilities to protect Data. Internal users are also subject to contractual confidentiality requirements. 3. The download functionality of Data from the FDP is disabled by default, and access to this is controlled by the	Section 12 & 16	Tolerate	Remote	Significant	Low

Risk No	Risk	Steps to mitigate the risk	DPIA section in which step is described	Effect on risk. Tolerate / Terminate / Treat / Transfer	Likelihood of harm Remote / Possible / Probable	Severity of harm Minimal / Significant / Severe	Residual risk None / Low / Medium / High
		Product Owner which ensures appropriate governance in in place. 4. Role Based Access Controls and Purpose Based Access Controls are in place to limit access to Pseudonymised Data to only those with a legitimate need e.g. developers of the Product. 5. The FDP access audit logs ensure that all access is logged and can be fully audited.					
2	Pseudonymised Data may be processed beyond the appropriate retention period.	1.Compliance with the Data Security Protection Toolkit (DSPT) requires Records Management policies to be in place. 2.The data is kept in line with NHS Records Management Code of Practice. 3. The business area responsible for the Data have a Records Management Information Co-ordinator who will provide advice on how long Data should be retained at the point the Dashboard is decommissioned.	Section 13	Tolerate	Remote	Minimal	Low
3	Insufficient organisational measures are in place to ensure appropriate security of the Personal Data	1.Appropriate organisational measures in relation to Data controls and governance are in place to ensure the security of the Data. 2. Organisational measures are adhered to across the Data platform.	Set out in the Overarching FDP DPIA and Section 12 & 16 above	Tolerate	Remote	Minimal	Low

Risk No	Risk	Steps to mitigate the risk	DPIA section in which step is described	Effect on risk. Tolerate / Terminate / Treat / Transfer	Likelihood of harm Remote / Possible / Probable	Severity of harm Minimal / Significant / Severe	Residual risk None / Low / Medium / High
	(e.g. policies, procedures, disciplinary controls)	Any breaches are reported in line with these. 3. Role Based Access Controls and Purpose Based Access Controls are in place to limit access to Data.					
4	Insufficient technical measures are in place to ensure appropriate security of the Personal Data (e.g. encryption, access controls)	1. Data is encrypted in storage 2. All Data to and from the platform is encrypted in transit using at least TLS1.2 3. SLSP in place	Set out in the Overarching FDP DPIA and Section 12 & 16 above	Tolerate	Remote	Minimal	Low
5	Pseudonymised Data could be deliberately manipulated by an internal bad actor in some way to re-identify individual people	1. External suppliers are Processors on contracts with relevant security and data protection clauses contained within the agreements. Internal security and data protection processes are in place within NHS England. 2. Staff are trained and fully aware of their responsibilities when analysing Data to only use the minimum required for their purpose and that it is a criminal offence under the DPA 2018 to knowingly re-identify an individual	Set out in the Overarching FDP DPIA and Section 11, 12 & 16 above	Tolerate	Remote	Significant	Low

Risk No	Risk	Steps to mitigate the risk	DPIA section in which step is described	Effect on risk. Tolerate / Terminate / Treat / Transfer	Likelihood of harm Remote / Possible / Probable	Severity of harm Minimal / Significant / Severe	Residual risk None / Low / Medium / High
		<p>3. Contracts of employment and other organisational policies provide further safeguards against Data misuse</p> <p>4. Specific Data Processing instructions are provided to the Platform Contractor which limits their Processing of the Pseudonymised Data to this Product, and which prohibits any reidentification</p> <p>5. The download functionality of Data from the FDP is disabled by default, and access to this is controlled by the Product Owner which ensures appropriate governance in in place.</p>					
6	Unsuppressed small numbers in Aggregated Data made available via the Product Dashboard could lead to the identification of an individual	As the Aggregated Data made available via the Product Dashboard has small numbers included. Whilst small numbers are shown, they have been further aggregated at regional level and it is unlikely that an individual could be re-identified in the Data or for the output to be linked with other Data which would enable re-identification to the users of the dashboard. However, a risk assessment focused on the potential for re-identification from the small numbers will be conducted to ensure that it is not possible. The Data	Section 3 & 7	Tolerate	Remote	Minimal	None

Risk No	Risk	Steps to mitigate the risk	DPIA section in which step is described	Effect on risk. Tolerate / Terminate / Treat / Transfer	Likelihood of harm Remote / Possible / Probable	Severity of harm Minimal / Significant / Severe	Residual risk None / Low / Medium / High
		is therefore considered to be Aggregated Data which is Anonymous.					
7	Insufficient testing has taken place to assess and improve the effectiveness of technical and organisational measures supporting the Product.	1. Full details are described in the Overarching FDP DPIA. 2. For national Products migrating from Foundry to FDP, there is no change in the Product, its operation or the technical measures supporting it. New governance processes for migrating existing Products have been put in place, including approval of relevant DPIAs by the DGG and the Deputy SIRO. This updated DPIA has also been put in place to assess the risks consistently across all national Products.	Set out in the Overarching FDP DPIA and Section 3, 12 & 16 above	Tolerate	Remote	Minimal	Low
8	Failure to provide appropriate transparency information to data subjects.	1. The NHSE General FDP Privacy Notice has been published and a separate Product Privacy Notice has been produced and will be published on NHS England's website with a link to it from the General FDP Privacy Notice.	Sections 8 and 9	Tolerate	Remote	Significant	Low

Risk No	Risk	Steps to mitigate the risk	DPIA section in which step is described	Effect on risk. Tolerate / Terminate / Treat / Transfer	Likelihood of harm Remote / Possible / Probable	Severity of harm Minimal / Significant / Severe	Residual risk None / Low / Medium / High
9	Increased access to Special Category Personal Data is given to staff who would not normally access that Data within their role.	1. Role Based and Purpose Based Access Controls are in place. The addition of the Restricted View function to sit over the Purpose Based Access Controls ensures only those who need access to Special Category Personal Data are able to access this. 2. The Data Processed to produce the Product has been Pseudonymised before being ingested into FDP. 3. Only analysts responsible for developing the Product have access to the Pseudonymised Data.	Section 12 & 16	Treat	Possible	Minimal	Low
10	The platform becomes inaccessible to users which could cause delays in the management of availability of Data.	1. The FDP Contractor is required to have Business Continuity Plans in place. 2. The Product Owner has Business Continuity Plans in place which cover the inaccessibility/unavailability of the Product.	Section 16	Tolerate	Remote	Significant	Low
11	Inadequate data quality in source IT systems results in errors, inconsistencies and missing information that	1. The Product will only collect a subset of Personal Data from existing NHSE datasets. The Product will not collect Personal Data directly from individuals.	Section 14	Tolerate	Remote	Significant	Low

Risk No	Risk	Steps to mitigate the risk	DPIA section in which step is described	Effect on risk. Tolerate / Terminate / Treat / Transfer	Likelihood of harm Remote / Possible / Probable	Severity of harm Minimal / Significant / Severe	Residual risk None / Low / Medium / High
	could compromise the integrity and reliability of the Data in the Product.	2. It is our responsibility to ensure that all Data that is ingested into FDP for use in this Product is up to date and accurate for the purposes for which it is Processed within the Product. We will use our existing processes relating to the source datasets for maintaining accuracy.					
12	Users will attempt to access FDP and the Product from outside the UK, increasing the data security risk.	<p>1. It is clearly articulated within the FDP IG Framework that no personal/patient data should leave or be accessible from outside of the UK without the express prior approval from the Data Governance Group.</p> <p>2. It is within the Platform Contract that no access to the system should take place from outside the UK.</p> <p>3. There are technical security measures in place to prevent access from outside the UK.</p>	Section 17	Treat	Remote	Minimal	Low
13	Users will not have their permissions revoked when they leave their role/	1. As part of migrating national Products from Foundry to FDP, any users who have not accessed a migrating Product since January 2024 will have their access disabled. User accounts are also checked on a	Section 12 & 16	Treat	Remote	Significant	Low

Risk No	Risk	Steps to mitigate the risk	DPIA section in which step is described	Effect on risk. Tolerate / Terminate / Treat / Transfer	Likelihood of harm Remote / Possible / Probable	Severity of harm Minimal / Significant / Severe	Residual risk None / Low / Medium / High
	organisation and may continue to have access to Data they are no longer entitled to access	Product-by-Product basis with Product Owners regarding who should transition and if their access is still valid.					

20. Actions

Redaction Rationale – The information below has been redacted as this includes personal information, this has been completed in line with Section 40 (2) of the Freedom of Information Act 2000.

This section draws together all the actions that need to be taken in order to implement the risk mitigation steps that have been identified above, or any other actions required.

Action No	Actions required. (Date and responsibility for completion)	Risk No impacted by action	Action owner (Name and role)	Date to be completed
1	A risk assessment is to be undertaken on the risk associated with small numbers being included in the Dashboard. An ongoing review of unsuppressed Data to ensure it remains Anonymous Aggregated Data or Operational Data when any new Data items are added to the Product, or when any changes are made the Dashboard visualisations. If new Data items are added to the Product this DPIA will be updated.	6	Nasi [REDACTED] Mahmood [REDACTED]	Ongoing at each change of the Product and update to this DPIA

21.Completion and signatories

The completed DPIA should be submitted to the NHSE Privacy Transparency and Trust IG Team for review.

The IAO (Information Asset Owner) should keep the DPIA under review and ensure that it is updated if there are any changes (to the nature of the Processing, including new data items Processed, change of purpose, and/or system changes)

The DPIA accurately reflects the Processing and the residual risks have been approved by the Information Asset Owner:

Information Asset Owner (IAO) Signature and Date

Name	
Signature	
Date	

FOR DATA PROTECTION OFFICER USE ONLY

22. Summary of high residual risks

Risk no.	High residual risk summary
----------	----------------------------

Summary of Data Protection Officer advice:

Name	
Signature	
Date	
Advice	

Where applicable: ICO (Information Commissioners Office) consultation outcome:

Name	
Signature	
Date	
Consultation outcome	

Next Steps:

- DPO to inform stakeholders of ICO consultation outcome
- IAO along with DPO and SIRO (Senior Information Risk Owner) to build action plan to align the Processing to ICO's decision

Annex 1: Defined terms and meaning

The following terms which may be used in this Document have the following meaning:

Defined Term	Meaning
Aggregated Data	Counts of Data presented as statistics so that Data cannot directly or indirectly identify an individual.
Anonymisation	Anonymisation involves the application of one or more anonymisation techniques to Personal Data. When done effectively, the anonymised information cannot be used by the user or recipient to identify an individual either directly or indirectly, taking into account all the means reasonably likely to be used by them. This is otherwise known as a state of being rendered anonymous in the hands of the user or recipient.
Anonymised Data	Personal Data that has undergone Anonymisation.
Anonymous Data	Anonymised Data, Aggregated Data and Operational Data.
Approved Use Cases	Means one of the five initial broad purposes for which Products in the Data Platform can be used as outlined in Part 1 of Schedule 2 (Approved Use Cases and Products) of the IG Framework, or any subsequent broad purpose agreed to be a use case through the Data Governance Group
Categorisation of Data	<p>Means one of the following categories of Data:</p> <ul style="list-style-type: none">• Directly Identifiable Personal Data• Pseudonymised Data• Anonymised Data,• Aggregated Data• Operational Data <p>In the case of Directly Identifiable Personal Data or Pseudonymised Data this could be Personal Data or Special Category Personal Data.</p>
Common Law Duty of Confidentiality	The common law duty which arises when one person discloses information to another (e.g. patient to clinician) in circumstances where it is reasonable to expect that the information will be held in confidence.
Confidential Patient Data	Information about a patient which has been provided in circumstances where it is reasonable to expect that the information will be held in confidence, including Confidential Patient Information.

Defined Term	Meaning
Confidential Patient Information	Has the meaning given in section 251(10) and (11) of the NHS Act 2006. See Appendix 6 of the National Data Opt Out Operational Policy Guidance for more information ¹
Controller	Has the meaning given in UK GDPR being the natural or legal person, public authority, agency, or other body which, alone or jointly with others, determines the purposes and means of the Processing of Personal Data (subject to Section 6 of the Data Protection Act 2018)
Data Governance Group	Means a national group established by NHS England to provide oversight to the approach to Data Processing and sharing across all Instances of the Data Platform and NHS-PET which will include membership from across FDP User Organisations
Data Platform or Platform	The NHS Federated Data Platform
Data Processing Annex	The annex to the schedule containing Processing instructions in the form set out in the FDP Contracts.
Data Protection Legislation	The Data Protection Act 2018, UK GDPR as defined in and read in accordance with that Act, and all applicable data protection and privacy legislation, guidance, and codes of practice in force from time to time
Direct Care	A clinical, social, or public health activity concerned with the prevention, investigation and treatment of illness and the alleviation of suffering of individuals. It includes supporting individuals' ability to function and improve their participation in life and society. It includes the assurance of safe and high-quality care and treatment through local audit, the management of untoward or adverse incidents, person satisfaction including measurement of outcomes undertaken by one or more registered and regulated health or social care professionals and their team with whom the individual has a legitimate relationship for their care ² .
Directly Identifiable Personal Data	Personal Data that can directly identify an individual.
DPIA(s)	Data Protection Impact Assessments in a form that meets the requirements of UK GDPR
FDP	Federated Data Platform
FDP Contract	The NHS-PET Contract and the Platform Contract
FDP Contractor(s)	The NHS-PET Contractor and/or the Platform Contractor

¹ <https://digital.nhs.uk/services/national-data-opt-out/operational-policy-guidance-document/appendix-6-confidential-patient-information-cpi-definition>

² See the National Data Guardian Direct Care Decision Support Tool:
https://assets.publishing.service.gov.uk/media/5f2838d7d3bf7f1b1ea28d34/Direct_care_decision_support_tool.xlsx

Defined Term	Meaning
FDP Programme	The NHS England Programme responsible for the procurement and implementation of the FDP across the NHS
FDP User Organisations	NHS England, ICBs, NHS Trusts and other NHS Bodies (including a Commissioned Health Service Organisation) who wish to have an Instance of the Data Platform and who have entered into an MoU with NHS England. In the case of a Commissioned Health Service Organisation, the MoU is also to be entered into by the relevant NHS Body who has commissioned it
General FDP Privacy Notice	A privacy notice providing information on the Personal Data Processed in the Data Platform and by NHS-PET generally, including the Approved Use Cases for which Products will Process Personal Data
ICB	Integrated Care Board
ICS	Integrated Care System
Incident	An actual or suspected Security Breach or Data Loss Incident
Instance	A separate instance or instances of the Data Platform deployed into the technology infrastructure of an individual FDP User Organisation
National Data Opt Out	The Department of Health and Social Care's policy on the National Data Opt Out which applies to the use and disclosure of Confidential Patient Information for purposes beyond individual care across the health and adult social care system in England. See the National Data Opt Out Overview ³ and Operational Policy Guidance for more information ⁴
NHS-PET Contract	The Contract between NHS England and the NHS-PET Contractor relating to the NHS-PET Solution dated 28 November 2023 as may be amended from time to time in accordance with its terms
NHS-PET Contractor	IQVIA Ltd
NHS-PET Solution	The privacy enhancing technology solution which records Data flows into the Data Platform and where required treats Data flows to de-identify them.
Ontology	Is a layer that sits on top of the digital assets (Datasets and models). The Ontology creates a complete picture by mapping Datasets and models used in Products to object types, properties, link types, and action types. The Ontology

³ <https://digital.nhs.uk/services/national-data-opt-out/understanding-the-national-data-opt-out>

⁴ <https://digital.nhs.uk/services/national-data-opt-out/operational-policy-guidance-document>

Defined Term	Meaning
	creates a real-life representation of Data, linking activity to places and to people.
Operational Data	Items of operational Data that do not relate to individuals eg stocks of medical supplies.
Personal Data	Has the meaning given in UK GDPR being any information relating to an identified or identifiable natural person ('Data subject'); an identifiable natural person is one who can be identified, directly or indirectly, in particular by reference to an identifier such as a name, an identification number, location Data, an online identifier or to one or more factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity of that natural person . For the purposes of this DPIA this also includes information relating to deceased patients or service users. Personal Data can be Directly Identifiable Personal Data or Pseudonymised Data.
Personal Data Breach	Has the meaning given in UK GDPR being a breach of security leading to the accidental or unlawful destruction, loss, alteration, unauthorised disclosure of, or access to, Personal Data transmitted, stored, or otherwise Processed
Platform Contract	The agreement between NHS England and the Platform Contractor in relation to the Data Platform dated 21 November 2023 as may be amended from time to time in accordance with its terms
Platform Contractor	Palantir Technologies UK Ltd
Product	A product providing specific functionality enabling a solution to a business problem of an FDP User Organisation operating on the Data Platform.
Product Privacy Notice	A privacy notice providing information on the Personal Data Processed in the Data Platform and by NHS-PET in relation to each Product, including the purposes for which the Product Processes Personal Data
Process or Processing	Has the meaning given in UK GDPR being any operation or set of operations which is performed on Personal Data or on sets of Personal Data, whether or not by automated means, such as collection, recording, organisation, structuring, storage, adaptation or alteration, retrieval, consultation, use, disclosure by transmission, dissemination or otherwise making available, alignment or combination, restriction, erasure, or destruction
Processor	Has the meaning given in UK GDPR being a natural or legal person, public authority, agency, or other body which Processes Personal Data on behalf of the Controller
Programme	The Programme to implement the Data Platform and NHS-PET across NHS England, NHS Trusts and ICBs

Defined Term	Meaning
Pseudonymisation	Has the meaning given in UK GDPR being the Processing of Personal Data in such a manner that the Personal Data can no longer be attributed to a specific individual without the use of additional information, provided that such additional information is kept separately and is subject to technical and organisational measures to ensure that the Personal Data are not attributed to an identified or identifiable natural person
Pseudonymised Data	Personal Data that has undergone Pseudonymisation
Purpose Based Access Controls or PBAC	Means user access to Data is based on the purpose for which an individual needs to use Data rather than their role alone as described more fully in Part 2 of Schedule 3
Role Based Access Controls or RBAC	Means user access is restricted to systems or Data based on their role within an organisation. The individual's role will determine what they can access as well as permission and privileges they will be granted as described more fully in Part 2 of Schedule 3
Special Category Personal Data	Means the special categories of Personal Data defined in Article 9(1) of UK GDPR being Personal Data revealing racial or ethnic origin, political opinions, religious or philosophical beliefs, or trade union membership, and the Processing of genetic Data, biometric Data for the purpose of uniquely identifying a natural person, Data concerning health or Data concerning a natural person's sex life or sexual orientation.
Transition Phase	Is the first phase of rolling out the Data Platform which involves NHS England and local FDP User Organisations who currently use Products, moving their existing Products onto the new version of the software that is in the Data Platform. There is no change to the Data that is being processed, the purposes for which it is processed or the FDP User Organisations who are Processing the Data during the Transition Phase. The Transition Phase will start in March 2024 and is expected to run until May 2024.
UK GDPR	UK GDPR as defined in and read in accordance with the Data Protection Act 2018